Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation.

@article{Raichlin2007ConversionTS,
  title={Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation.},
  author={Eugenia Raichlin and Jang-Ho Bae and Zain Khalpey and Brooks S. Edwards and Walter Karl Kremers and Alfredo L. Clavell and Richard J. Rodeheffer and Robert P. Frantz and Charanjit S. Rihal and Amir Lerman and Sudhir Shyam Kushwaha},
  journal={Circulation},
  year={2007},
  volume={116 23},
  pages={2726-33}
}
BACKGROUND We investigated the potential of conversion to sirolimus (SRL) as a primary immunosuppressant in attenuating cardiac allograft vasculopathy progression. METHODS AND RESULTS Twenty-nine cardiac transplant recipients were converted to SRL 3.8+/-3.4 years after transplantation with complete calcineurin inhibitor (CNI) withdrawal. Secondary immunosuppressants (azathioprine or mycophenolate) and steroids remained unchanged. Forty patients (controls) 4.8+/-4.0 years from transplantation… CONTINUE READING
67 Citations
44 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Similar Papers

Loading similar papers…